Jill Wechsler

Jill Wechsler is BioPharm International's Washington Editor, jillwechsler7@gmail.com.


Medicare Limits Aduhelm Coverage to Patients in Clinical Trials

The Centers for Medicare and Medicaid Services took action to limit prescribing and use of Biogen’s new and controversial Alzheimer’s treatment Aduhelm (aducanumab).

FDA Keeps New Drugs Coming

FDA maintained a steady pace in 2021 in approving important new therapies for market, including new vaccines and treatments for COVID-19.

Here Come the COVID-19 Treatment Options

FDA authorized emergency use of Pfizer’s oral antiviral drug to make the drug available as quickly as possible.

Califf Gains Bipartisan Support for FDA Confirmation

General agreement that FDA needs a confirmed commissioner may speed Califf’s appointment.

Drug Costs Central Issue in Budget Battles

President Joe Biden highlighted how current proposals for curbing outlays on pharmaceuticals will help protect patients’ health and save the government billions.

FDA Grapples with the Promise and Perils of Gene Therapy

High price tags threaten to block patient access to potentially life-saving cures and treatments.

Pandemic Alters Policies and Practices for Drug Development and Regulation

The need for medicines to combat COVID-19 has impacted the way regulatory agencies carry out their operations.

New Cures 2.0 Legislation Advances Biomedical Research and Care

Leading legislators have launched the campaign to enact a second version of the 21st Century Cures Act.

Califf Named to Head FDA

The White House has nominated Robert Califf to head FDA, ending months of uncertainty about the future path for the high-profile agency.